Oculis Aktie

Kaufen

Verkaufen

16,95 EUR -0,25 EUR -1,45 %

21:57:28

FSE

19,67 USD +0,21 USD +1,08 %

nachbörslich22:15:59

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Bei einem anderen Broker handeln

Marktkap.906,30 Mio. EUR

Div. Rendite0,00%

WKNA3D8QG

ISINCH1242303498

SymbolOCS

Oculis Aktien News

Sortieren:Datum Meistgelesen

09.06.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

05.06.25GlobeNewswireOculis Publishes Results of 2025 Annual General Meeting

03.06.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

03.06.25GlobeNewswireOculis to Participate in Upcoming June Investor Conferences

09.05.25GlobeNewswireOculis Publishes Invitation to the Annual General Meeting

08.05.25GlobeNewswireOculis Reports Q1 Financial Results and Provides Company Update

07.05.25GlobeNewswireOculis to Present at Upcoming May Investor Conferences

01.05.25GlobeNewswireOculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

25.04.25GlobeNewswireOculis Updates Share Capital

15.04.25GlobeNewswireOculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

10.04.25GlobeNewswireOculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

09.04.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

01.04.25GlobeNewswireOculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

20.03.25GlobeNewswireOculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

14.03.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

11.03.25GlobeNewswireOculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

03.03.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

14.02.25GlobeNewswireOculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

08.02.25GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

31.01.25GlobeNewswireOculis updates share capital for its existing at-the-market offering program

21.01.25GlobeNewswireOculis Publishes Notification of Major Changes in Voting Rights

20.01.25GlobeNewswireOculis Publishes Notification of Major Changes in Voting Rights

06.01.25GlobeNewswireOculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Cla

04.01.25GlobeNewswireOculis Publishes Notification of Major Changes in Voting Rights

06.12.24GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

29.11.24GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

27.11.24GlobeNewswireOculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

13.11.24GlobeNewswireOculis to Present at the Stifel 2024 Healthcare Conference

07.11.24GlobeNewswireOculis Reports Q3 2024 Financial Results and Provides Company Updates

21.10.24GlobeNewswireOculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

02.10.24GlobeNewswireOculis Announces Appointment of Daniel S. Char as Chief Legal Officer

27.08.24GlobeNewswireOculis Publishes Consolidated Q2 Financial Statements and MD&A

27.08.24GlobeNewswireOculis Reports Q2 Financial Results and Provides Recent Company Update

15.08.24GlobeNewswireOculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

10.06.24GlobeNewswireOculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

04.06.24GlobeNewswireOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

30.05.24GlobeNewswireOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

17.05.24GlobeNewswireOculis updates share capital for its existing at-the-market offering program

08.05.24GlobeNewswireOculis Reports Q1 2024 Financial Results and Provides Company Updates

07.05.24GlobeNewswireOculis Publishes Invitation to the Annual General Meeting

Oculis News

Oculis News: auf dieser Seite finden Sie alle Oculis News und Nachrichten zur Oculis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Oculis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Oculis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.